Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Clinical trial NCT02658812 · TERMINATED

Trial details

NCT number: NCT02658812
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Chest Wall Neoplasm Recurrent Breast Carcinoma Recurrent Inflammatory Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7 Stage IV Inflammatory Breast Carcinoma

Start date: 2016-08-01
Primary completion: 2021-12-01
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.